Altimmune Inc (NASDAQ:ALT) currently has a daily average trading volume of 5.31M but it saw 2820749 shares traded in last market. With a market cap of 595.56M USD, the company’s current market price of $8.40 came rising about 4.87 while comparing to the previous closing price of $8.01. In past 52 weeks, the stock remained buoying in the range of price level as high as $14.84 and as low as $2.09.
Taking a look at 20-day trading activity of Altimmune Inc (ALT) gives us an average price of $9.09, while its current price level is -43.40% below from 52-week high level whereas it is 301.91% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $9.79 while that of 200 days or SMA-200 reads an average of $5.79. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.58% during that period while stretching the period over a month that increases to 8.93%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 42.29 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Goldman which initiated the stock as “Neutral” in its note to investors issued on January 24, 2024, recommending a price target of $13 for it. Goldman downgraded its recommendation for the stock as a “Neutral” from “Buy” on March 22, 2023 while assigning a price target range of $20-$6. Goldman also issued its recommendations for the stock as it initiated the price target for the stock is $20.
Over the week, ALT’s stock price is moving -5.62% down while it is -22.72% when we observe its performance for the past one month. Year-to-date it is -25.33% down and over the past year, the stock is showing an upside performance of 102.90%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2023, when its quarterly earnings per share (EPS) of -$0.54 beaten by the consensus estimate of -$0.43 for the same. For ALT, analysts are forecasting an EPS-growth rate of 39.80% for current year and estimate for EPS growth in next year is -77.00%.
Currently, Altimmune Inc’s total number of outstanding shares is 70.68M with 0.78% of that held by the insiders while 51.46% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -45.53% and return on equity (ROE) at -46.63%. Stock’s beta reads 0.12. Stock has a price to book (P/B) ratio of 3.06 while price to sale or P/S ratio amounts to 1385.02. Its return on asset (ROA) is -42.36% on average.
